Dezima's CETP inhibitor could be 'cheaper, oral' alternative to PCSK9s
This article was originally published in Scrip
Executive Summary
Dezima Pharma has published highly positive results of the Phase IIb TULIP study with its CETP inhibitor, TA-8995, in the Lancet. The potency demonstrated by Dezima's product suggests it has potential as a more cost-effective option for lowering cholesterol than the PCSK9 inhibitor approach.